ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
Latest Information Update: 23 Apr 2025
At a glance
- Drugs Docetaxel (Primary) ; Gemcitabine (Primary) ; Pegargiminase (Primary)
- Indications Non-small cell lung cancer; Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Jun 2024 Trial design from this study assessing the safety, tolerability, to determine the recommended phase II dose (R2PD) and evaluate the efficacy of this combination in patients with previously treated metastatic non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) with an alternative dosing regimen than that used in STS based on the mechanism of action were presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 24 May 2024 Planned End Date changed from 30 Jun 2032 to 31 Dec 2032.
- 24 May 2024 Planned primary completion date changed from 30 Jun 2027 to 31 Dec 2027.